Perry Shieh, MD
Neurology · Los Angeles, CANPI 1588683395
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 25.0% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,486 payments — averaging $982.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$611K
- Biogen$507K
- AstraZeneca$353K
- Genentech USA, Inc.$245K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$142K
- Argenx US, Inc.$139K
- plus $446K from 25 others
Across 683 payments — averaging $8424.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$2M
- Pfizer$1.3M
- Biogen$1.2M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$380K
- Sanofi$244K
- PTC Therapeutics, Inc.$191K
- plus $425K from 13 others
What the payments were for
- Consulting fees$848,00135%
- Speaking & faculty fees$1,198,96249%
- Travel & lodging$292,89012%
- Food & beverage$55,8462%
- Education$46,1502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 295 | $610,613 |
| Biogen | 526 | $507,085 |
| AstraZeneca | 459 | $352,779 |
| Genentech USA, Inc. | 198 | $244,578 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 254 | $141,670 |
| Argenx US, Inc. | 143 | $138,738 |
| UCB, Inc. | 207 | $126,156 |
| Catalyst Pharmaceuticals, Inc. | 82 | $91,066 |
| CSL Behring | 66 | $49,474 |
| Grifols USA, LLC | 68 | $46,309 |
| Sanofi-aventis U.S. LLC | 9 | $30,192 |
| Amgen | 22 | $19,856 |
| ITF Therapeutics LLC | 17 | $13,511 |
| Pfizer | 11 | $8,989 |
| F. Hoffmann-la Roche AG | 5 | $8,967 |
| Genentech, Inc. | 31 | $8,093 |
| Janssen Scientific Affairs, LLC | 10 | $7,165 |
| Spark Therapeutics, Inc. | 9 | $6,785 |
| PTC Therapeutics, Inc. | 18 | $6,106 |
| Grifols Shared Services North America, Inc. | 13 | $4,955 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $4,380 |
| Lupin Inc. | 1 | $3,250 |
| Sanofi | 2 | $2,829 |
| Zogenix Inc. | 1 | $2,500 |
| Novartis | 8 | $1,938 |
| Amicus Therapeutics, Inc. | 1 | $1,864 |
| NS Pharma, Inc. | 16 | $1,686 |
| Novartis Pharma AG | 1 | $175 |
| Octapharma USA, Inc. | 1 | $103 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Kedrion Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$454,511
- ULTOMIRIS$263,305
- EVRYSDI$204,997
- VYVGART$120,516
- ZOLGENSMA$118,021
- Exondys 51$103,067
- FIRDAPSE$69,716
- Rystiggo$59,471
- SOLIRIS$50,899
- Zilbrysq$50,376
- Gamunex-C$49,803
- Hizentra$48,492
- Non-Covered Product$32,618
- NEXVIAZYME$30,034
- LUMIZYME$30,034
- AGAMREE$20,339
- Elevidys$17,622
- UPLIZNA$11,930
- VYVGART HYTRULO$8,052
- Fintepla$2,500
How this compares
$2,441,849 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 212 | $2,656,155 |
| EvrysdiRisdiplam | 48 | $1,304,847 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 76 | $997,529 |
| NexviazymeAvalglucosidase Alfa-Ngpt | 12 | $588,025 |
| ZilbrysqZilucoplan Sodium | 13 | $464,556 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 22 | $369,666 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $328,411 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 41 | $283,981 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 25 | $233,476 |
| Mycophenolate Mofetil | 79 | $17,113 |
| Epinephrine | 13 | $4,084 |
| Pyridostigmine Bromide | 34 | $2,550 |
| Prednisone | 65 | $486 |
| Gabapentin | 18 | $365 |
| Baclofen | 12 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $4,380 | $2,656,155212 claims |
| Genentech USA, Inc.Evrysdi | $244,578 | $1,304,84748 claims |
| Grifols USA, LLCGamunex-C | $46,309 | $997,52976 claims |
| SanofiNexviazyme | $2,829 | $588,02512 claims |
| UCB, Inc.Zilbrysq | $126,156 | $464,55613 claims |
| Kedrion Biopharma, Inc.Gammaked | $13 | $328,41117 claims |
| CSL BehringPrivigen | $49,474 | $283,98141 claims |
| PfizerOctagam | $8,989 | $233,47625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
- Michele TagliatiLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.